323 related articles for article (PubMed ID: 32715967)
1. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
Gharaibeh M; Bonafede M; McMorrow D; Hernandez EJM; Stolshek BS
J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
Incerti D; Hernandez EJM; Tkacz J; Jansen JP; Collier D; Gharaibeh M; Moore-Schiltz L; Stolshek BS
J Manag Care Spec Pharm; 2020 Oct; 26(10):1236-1242. PubMed ID: 32996384
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept.
Bonafede M; Oko-Osi H; Gharaibeh M; Manjelievskaia J; Lopez-Gonzalez L; Collier DH; Stolshek BS
J Manag Care Spec Pharm; 2020 Feb; 26(2):211-220. PubMed ID: 31823689
[TBL] [Abstract][Full Text] [Related]
7. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
[TBL] [Abstract][Full Text] [Related]
8. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
[TBL] [Abstract][Full Text] [Related]
9. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
11. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
[TBL] [Abstract][Full Text] [Related]
12. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
13. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
14. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
16. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
17. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
18. Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study.
Gu T; Shah N; Deshpande G; Tang DH; Eisenberg DF; Harrison DJ
J Health Econ Outcomes Res; 2016; 3(2):122-131. PubMed ID: 37663319
[No Abstract] [Full Text] [Related]
19. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
